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Abstract 
NAD(P)H quinone oxidoreductase 1 (NQO1) is involved in antioxidant defence and 
protection from cancer, stabilizing the apoptosis regulator p53 towards degradation.  
Here, we studied the enzymological, biochemical and biophysical properties of two 
cancer-associated variants (p.R139W and p.P187S). Both variants (especially p.187S) 
have lower thermal stability and greater susceptibility to proteolysis compared to the 
wild-type. p.P187S also has reduced activity due to a lower binding affinity for the 
FAD cofactor as assessed by activity measurements and direct titrations. Native gel 
electrophoresis and dynamic light scattering also suggest that p.P187S has a higher 
tendency to populate unfolded states under native conditions. Detailed thermal 
stability studies showed that all variants irreversibly denature causing dimer 
dissociation, while addition of FAD restores the stability of the polymorphic forms to 
wild-type levels. The kinetic destabilization induced by polymorphisms as well as the 
kinetic protection exerted by FAD was confirmed by measuring denaturation kinetics 
at temperatures close to physiological. Our data suggest that the main molecular 
mechanisms associated with these cancer-related variants are their low binding 
affinity for FAD and/or kinetic instability. Thus, pharmacological chaperones may be 
useful in the treatment of patients bearing these polymorphisms. 
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NQO1*2; NQO1*3; kinetic instability 
Abbreviations:  BS
3
, bissulfosuccinimidyl-suberate; CD, circular dichroism; EDC, 
N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride; DSC, differential 
scanning calorimetry; DSF, Differential scanning fluorimetry; ITC, isothermal 
titration calorimetry; MMC, mitomycin C; NQO1, NAD(P)H quinone oxidoreductase 
1; NQO2, dihydronicotinamide riboside quinone oxidoreductase 2; Tm, melting 
temperature. 
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Introduction 
NAD(P)H quinone oxidoreductase 1 (NQO1, DT-diaphorase, EC 1.6.5.2) is a 
mammalian enzyme which catalyses the two electron reduction of quinones and 
related substrates.  The enzyme belongs to a family which also contains mammalian 
dihydronicotinamide riboside (NRH) quinone oxidoreductase 2 (NQO2, EC 1.10.99.2) 
and bacterial enzymes such as MdaB [1-3].  The family members are typically 
dimeric and have an FAD cofactor bound to each subunit [4-7].  They catalyse the 
reduction of quinones (and related compounds) through a substituted enzyme (“ping-
pong”) mechanism in which NAD(P)H (or NRH in the case of NQO2) enters the 
active site, reduces the FAD and exits as the oxidised form.  The second substrate then 
enters the active site and is reduced by the FADH2 [1;8;9]. 
 
There appear to be several physiological roles for NQO1.  Its enzymatic function has 
a minor role in vitamin K metabolism [10;11].  More generally, the enzyme catalyses 
the two electron reduction of quinone substrates, helping maintain the vitamin E 
derivative α-tocopherolquinone and ubiquinone (coenzyme Q) in their reduced, 
antioxidant forms [12;13].   The two electron reduction mechanism avoids the 
production of semiquinones [14].  These compounds are highly reactive and can 
induce the production of reactive oxygen species in the cell.  However, the protein 
also has non-catalytic roles.  In its reduced state, it binds to the apoptosis regulating 
protein p53 and stabilises it [15;16].  It also binds to the tumour suppressor protein 
p73 and the polyamine biosynthesis pathway enzyme ornithine decarboxylase [17;18].  
NQO1 interacts with the 20S proteasome reducing its activity, preventing it from 
degrading these proteins; however, partially unfolded forms of NQO1 can be 
efficiently degraded by the 20S proteasome [19]. 
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NQO1 is implicated in the molecular pathology of some cancers.  The amount of the 
enzyme is increased in some colon, liver, breast and lung tumours [20].  Consequently 
it has attracted interest as a possible target for cancer chemotherapy [21-24].  There 
are also some anti-cancer pro-drugs (e.g. mitomycin C (MMC) and a MMC analogue, 
EO9) which are reduced by NQO1 to the active form [25-27].  Interestingly there are 
two polymorphic forms of NQO1 which are associated with higher cancer risks.  The 
first one to be characterised, rs1800566 (c.C609T), is sometimes known as the 
NQO1*2 allele [28;29].  Globally the frequency of this allele in the human population 
is estimated to be 28%, rising to 51% in Han Chinese people 
(http://www.ensembl.org/Homo_sapiens/Variation/Population?db=core;r=16:6974464
5-69745645;v=rs1800566;vdb=variation;vf=1369178) [30].  It results in a proline to 
serine substitution at position 187 in the polypeptide sequence.  Biochemically it is 
associated with reduced cellular NQO1 protein levels [29].  Cells homozygous for this 
polymorphism have undetectable levels of NQO1 activity [29;31].  The reduction in 
activity also means that reductive activation of drugs such as MMC is less efficient 
and so cells expressing this variant form of NQO1 are less responsive to these 
compounds [28].  The p.P187S variant is highly susceptible to degradation by the 20S 
proteasome [19;32].  A large number of epidemiological studies have demonstrated 
that this allele is associated with increased cancer risks, although some question its 
significance – for recent examples, see [33-38].  Smokers who are homozygous for 
this mutation have an even greater risk of lung cancer than those who have at least 
one wild-type allele [39;40].  Homozygotes also have an increased susceptibility to 
benzene toxicity [41-43] 
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A second allele, NQO1*3 (rs1131341, c.C465T), is less well studied [44;45].  It 
results in an arginine to tryptophan substitution at position 139.  The global frequency 
of this allele is estimated to 2% with the highest known frequency (7%) in the Spanish 
Iberian population 
(http://www.ensembl.org/Homo_sapiens/Variation/Population?db=core;r=16:6974836
9-69749369;v=rs1131341;vdb=variation;vf=888801) [30].  p.R139W has also been 
associated with cancer, specifically childhood acute lymphoblastic leukaemia [46;47].  
Reduced responsiveness to MMC has also been reported [44;45].  Arginine 139 is 
positioned within the large catalytic domain on the periphery of the enzyme; it is in a 
loop and is solvent exposed.  Proline 187 is also positioned in a loop within the large 
catalytic domain and although more buried that arginine 139, is still solvent accessible.  
Neither residue forms part of the enzyme’s active site (Fig. 1). 
 
To better understand the fundamental molecular pathology of these two alleles, we 
expressed and purified the corresponding recombinant proteins, providing 
unprecedented detail on the effects of p.P187S and characterizing for the first time the 
effects of p.R139W at the molecular level.  This enabled us to propose that their 
reduced enzymatic activity results from protein instability (relative to the wild-type) 
and to investigate the role of FAD-mediated stabilization of NQO1. Our studies also 
provide a framework for the design of therapies aimed to rescue NQO1 functionality 
in patients bearing these polymorphisms. 
 
Materials and Methods 
Expression and purification of wild-type and variant NQO1 
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Hexahistidine-tagged human NQO1 was expressed in, and purified from, Escherichia 
coli cells.  The coding sequence for human NQO1 was amplified from I.M.A.G.E. 
clone 3349257 [48] and inserted into the E. coli expression vector pET46 Ek/LIC 
(Merck, Nottingham, UK).  Site-directed mutagenesis was carried out using the 
QuikChange method [49].  All coding sequences were verified by DNA sequencing 
(GATC Biotech, London, UK).  Competent E. coli HMS174(DE3) cells were 
transformed with the appropriate plasmid; a single colony resulting from this 
transformation was selected and grown shaking (200 rpm) at 37 °C overnight in 5 ml 
of LB supplemented with ampicillin (100 μgml-1).  This culture was diluted into 1 l of 
LB supplemented with ampicillin (100 μgml-1) and grown until mid-log phase (~4 h).  
The culture was induced by the addition of IPTG (1.7 mM) and grown for a further 3-
4 h.  The culture was centrifuged at 4200 g at 4 °C for 15 min, the pellets were 
resuspended in cold buffer R (50 mM Hepes-NaOH, pH 7.5, 150 mM NaCl, 10%(v/v) 
glycerol) and stored, frozen, at -80 °C.  Cells were thawed and disrupted by sonication 
on ice (3 × 30 s pulses at 100 W with 30 s intervals).  Insoluble material was removed 
by centrifugation (27000 g, 20 min at 4 °C).  The supernatant was applied to a nickel 
agarose resin column  (1 ml, His-Select™ Ni2+ affinity gel, Sigma-Aldrich) which had 
been pre-equilibrated with buffer A (buffer R, except 500 mM NaCl) and was allowed 
to pass through under gravity.  The column was washed with 50 ml of buffer A and 
the protein was eluted from the column by administration of two 2 ml volumes of 
buffer A supplemented with 250 mM imidazole.  Fractions containing NQO1 were 
identified by SDS PAGE and were dialysed overnight against 1 l of buffer R 
supplemented with 1 mM DTT at 4 °C.  The protein concentration was determined by 
the method of Bradford [50] and aliquots (50-100 μl) were stored at -80 °C. At least 
four independent purifications were performed for each of the NQO1 variants, and 
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several control experiments were carried out to confirm that key results are batch-
independent. The dimeric nature of NQO1 enzymes was routinely checked by size-
exclusion chromatography on HiLoad 16/60 Superdex 200 column (GE Healthcare). 
 
For spectroscopic and calorimetric studies, protein concentration was measured using 
extinction coefficients based on the primary sequences (wild-type and p.P187S, 
ε280nm=47900 M
-1
·cm
-1
; p.R139W, ε280nm=53400 M
-1
·cm
-1
).  Spectra of wild-type and 
R139W were corrected for the absorbance of FAD bound during purification (using 
ε280nm=22000 M
-1
·cm
-1 
and
 ε450nm=11300 M
-1
·cm
-1
 for free FAD). FAD was removed 
from NQO1 variants by performing dilution/concentration cycles in 2 M KBr, 50 mM 
Hepes-KOH pH 7.4 using 30 kDa cut-off filters and in this case their spectra were not 
corrected due to the FAD bound. The samples were considered to be FAD free when 
the A280/A450>200, buffer exchanged to 50 mM Hepes-KOH pH 7.4 and stored at -
80 °C.  FAD was dissolved in 50 mM HEPES-KOH pH 7.4 and its concentration 
measured using ε450nm=11300 M
-1
·cm
-1
. 
 
Enzyme kinetics 
NQO1 activity was measured in either 50 mM phosphate buffer pH 7.4 or 50 mM 
HEPES-NaOH pH 7.33 using NADH or NADPH as the electron donor and DCPIP 
(70 μM) as the electron acceptor; lysozyme (0.9 μM, Sigma) was included as a 
stabilising agent.  Initial reaction rates were determined from changes in A600 nm 
resulting from the reduction of DCPIP and correcting for the non-enzymatic rate of 
DCPIP reduction. All reactions were carried out in triplicate in a reaction volume of 
150 μl in 96-well plates at 37 °C in a Multiskan Spectrum plate reader (Thermo 
Scientific). Enzyme concentration was kept low enough to provide reliable 
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estimations of changes in A600nm.  To determine the effect of FAD on the rate of 
reaction catalysed by the p.P187S variant, aliquots of the protein (400 nM) were 
mixed with FAD (1-64 μM) and incubated on ice for ~5 min.  The enzyme was then 
diluted into the assay mix so that the final concentration of protein was 4 nM and the 
FAD concentration ranged from 10 to 640 nM.  Control experiments in the absence of 
protein were also carried out. 
 
 
The apparent Michaelis constant (Km,app) and turnover number (kcat,app) were 
determined from plots of enzyme-catalysed rate divided by enzyme concentration 
against the corresponding [NAD(P)H].  The data were fitted to equation (1) using 
non-linear curve fitting in GraphPad Prism 6.0 (GraphPad Software Inc., CA, USA).   
v/[E]=kcat,app[NAD(P)H]/Km,app+[NAD(P)H]  Equation (1) 
where kcat,app is the apparent turnover number;  Km,app is the apparent Michaelis-
Menten constant; [E] is the concentration of enzyme dimer.  Control experiments 
demonstrated that there was a linear relationship between the rate and the enzyme 
concentration in the range used in these experiments (data not shown).  Possible 
cooperative response to NADH or NADPH concentration was evaluated by analysis 
using linearized Hill plots. 
 
Tris-glycine native PAGE 
Wild type and variant enzymes were diluted to a final concentration of 3 μM dimer.  
An equal volume of native gel loading buffer (125 mM Tris–HCl, pH 8.8; 
20% (v/v) glycerol; 1% (w/v) DTT; 0.002% (w/v) bromophenol blue) was added and 
the samples were loaded onto a 10 % native polyacrylamide gel (stacking gel pH 6.8; 
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resolving gel pH 8.8) and electrophoresed at 20 mA until the dye front reached the 
end of the gel.  Gels were stained with Coomassie Blue. 
 
Crosslinking 
Increasing concentrations of the chemical cross-linkers bissulfosuccinimidyl-suberate 
(BS
3
) and N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC) 
were added to a constant concentration of NQO1 and variants (5 μM dimer in buffer 
R) which had been preincubated for 15 min at 37°C.  The reaction was allowed to 
proceed for 30 min at 37°C after which time it was stopped by the addition of SDS 
loading buffer (0.122 M Tris (pH 6.8); 4% (w/v) SDS; 19.5% (v/v) Glycerol; 0.13 M 
DTT; Bromophenol Blue 0.05% (w/v).  Reactions were analysed using SDS PAGE. 
 
Limited proteolysis 
Increasing concentrations of trypsin were added to samples of each NQO1 variant (3.5 
μM dimer in buffer R).  Proteolysis was allowed to proceed for 30 min at 37°C and 
was stopped by the addition of SDS tris-tricine loading buffer (12 % SDS (w/v); 6 % 
DTT (w/v); 30 % Glycerol; 150 mM Tris-HCl pH 7; 0.05 % Bromophenol Blue 
(w/v)).  Samples were denatured by heating at 95 °C for 5 min and analysed on 13% 
SDS tris-tricine gels [51]. 
 
Differential scanning fluorimetry (DSF) 
Wild-type NQO1, p.R139W and p.P187S were diluted to 2 μM (dimer), 2μM (dimer) 
and 10 μM (dimer) respectively.  The samples were loaded in triplicate into a Rotor-
Gene Q cycler (Qiagen) and the high resolution melt protocol selected.  Proteins were 
subjected to an increase in temperature form 25 °C to 95 °C in 1 K increments (no 
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gain optimisation selected).  The fluorescence of the cofactor, FAD, was exploited by 
exciting at 460 nm and measuring emission at 510 nm [52;53].  The melting 
temperature (Tm) of each variant was determined from the first derivative of the 
melting curve. 
 
Spectroscopic analyses 
All spectroscopic analyses were performed in Hepes-KOH 50 mM pH 7.4 unless 
otherwise indicated. Circular dichroism (CD) measurements were performed in a 
Jasco J-710 spectropolarimeter using 1 mm (Far-UV) or 5 mm (Near-UV/visible) 
path-length cuvettes. Thermal and wavelength scans were acquired using 5 (Far-UV, 
in K-phosphate 50 mM pH 7.4) or 10 µM (Near-UV/visible) NQO1.  Thermal scans 
by far-UV CD were registered at 222 nm from 10 to 80 °C at a 2 K/min scan rate, and 
the apparent Tm values were estimated as the maxima of the first derivative of thermal 
scans.  In some cases, FAD was added to a final concentration up to 0.25 mM.  
Fluorescence spectra were acquired in a Cary Eclypse spectrofluorometer using 3 mm 
path length cuvettes. All spectra were acquired at 25 °C at a 50-100 nm/min scan rates 
and 4-6 scans were registered and averaged. Dynamic light scattering (DLS) was 
carried out in a DynaPro MSX instrument (Wyatt) using 1.5 mm path length cuvettes 
and 5-10 µM protein (monomer).  Fifty spectra were acquired for each DLS analysis, 
averaged and used to determine the hydrodynamic radius (assuming a spherical 
particle shape) and polydispersity using the average autocorrelation function. 
 
To monitor isothermal denaturation of NQO1 variants, 230 µL of 50 mM Hepes-KOH 
pH 7.4 in the presence of 0-250 µM FAD were incubated at 37 °C or 42 °C for 10 min 
and then 20 µL of NQO1 enzymes (90 µM monomer) incubated with 0-250 µM 
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FAD were added and manually mixed (dead time between 10 and 60 s). The ellipticity 
at 222 nm was registered as a function of time for up to 50 h. To determine the 
apparent half-life for denaturation, kinetic traces were analyzed using a single 
exponential function. 
 
Differential scanning calorimetry (DSC) 
DSC studies were performed on a capillary VP-DSC differential scanning calorimeter 
(MicroCal, GE Healthcare) with a cell volume of 0.135 mL. Scans were performed at 
a 1-3 K/min in a temperature range of 5-80 °C using 5-30 µM NQO1 (monomer) in 
50 mM HEPES-KOH, pH 7.4. In some experiments, FAD was added to a final 
concentration up to 0.5 mM. 
 
Thermal denaturation of NQO1 variants was analyzed using a phenomenological two-
state irreversible denaturation model with non-first order kinetics [54-56], depicted 
by:  
FN
k
  
Where Nµ is the native oligomeric ensemble of NQO1 (i.e. a dimer with different 
number of FAD molecules bound/dimer), F an irreversibly aggregated state that 
cannot fold back, k is the rate constant for its conversion and 1/µ is the reaction order. 
Additional details on the analysis of DSC data can be found in the Supplementary 
Information. 
 
Isothermal titration calorimetry (ITC) 
Experiments were performed in a VP ITC200 microcalorimeter (GE Healthcare) with a 
cell volume of 0.135 mL. Cell samples contained 5-6 M NQO1 variants (dimer) in 
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Hepes-KOH 50 mM pH 7.4 and were titrated using 0.25 mM FAD by performing 30-
50 injections of 0.8-1.2 L each 180-240 s.  Data were corrected for heats of dilution 
by performing FAD titrations into buffer. After peak integration, binding isotherms 
were fitted using a sequential binding model with two binding sites or a one identical 
and independent type of sites model using the software provided by the manufacturer. 
Additional details on the analysis of ITC data can be found in the Supplementary 
Information. 
 
Results 
Expression, purification and dimerisation of wild-type and variant NQO1 
Wild type human NQO1 could be expressed in, and purified from, E. coli with a 
typical yield of 5 mg per litre of culture.  The variants p.R139W and p.P187S could 
also be expressed and purified albeit with slightly lower yields of 3 and 2 mg per litre 
of culture respectively (Supplementary Fig. S1a).  Solutions of purified wild-type and 
p.R139W proteins were an intense yellow colour whereas p.P187S was not; this 
indicated that p.P187S had substantially less FAD bound.  As expected, homodimers 
of the wild-type protein were detected by protein-protein crosslinking with both EDC 
and BS
3
 and size-exclusion chromatography.  Both variants also formed homodimers 
(Supplementary Fig. S1b,c,d).  FAD (0-80 μM) had no effect on the amount of BS3 
crosslinking observed (data not shown). 
 
Activity of wild-type and variant NQO1 
Wild-type NQO1 and p.R139W were active with both NADH and NADPH as 
electron donors and DCPIP as the electron acceptor (Fig. 2; Table 1); p.P187S had no 
detectable activity under these conditions (data not shown).  Pre-incubation of the 
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enzyme with excess FAD prior to its addition to the reaction recovered the activity of 
p.P187S (Supplementary Fig. S2) and increased the activity of wild-type and 
p.R139W (data not shown).  The kinetic constants for wild-type NQO1 and p.R139W 
are broadly similar; however, pR139W is slightly more active with NADH than the 
wild-type as judged by the specificity constant (kcat/Km; note that this parameter is not 
dependent on concentration of fixed substrate in the substituted enzyme mechanism 
[57]).  It has been reported previously that rat NQO1 exhibits negative cooperativity 
towards inhibitors which are competitive with respect to NAD(P)H [58].  Neither 
wild-type human NQO1 nor p.R139W exhibited cooperativity towards either NADH 
or NADPH (Supplementary Fig. S3; Table 1). 
 
Protein conformation and FAD binding 
As isolated, wild-type and p.R139W display similar hydrodynamic radii (3.60±0.05 
and 3.66±0.15 nm, respectively). The hydrodynamic radius of p.P187S is slightly 
larger (4.06±0.07 nm, p<0.01 using a t-test vs. WT or p.R139W), suggesting that the 
ensemble average conformation of P187S is slightly expanded (Fig. 3a,b) possibly 
due to the presence of low levels of partially unfolded states.  All three enzymes 
behave as monodisperse particles, with polydispersities in the range of ~10-15% (Fig. 
3b). Interestingly, addition of FAD seems to slightly reduce the hydrodynamic size of 
p.P187S while having no significant effect on wild-type and p.R139W (Fig. 3a). 
Consistent with these effects on the overall conformation of p. R139W and p.P187S, 
the far-UV CD spectra in the absence or presence of 50 M FAD revealed very 
similar secondary structure content in the three NQO1 variants (Fig. 3c).  The 
tryptophan emission spectra of wild-type and p.R139W show the same maxima 
(max=352 nm) and the higher intensity of p.R139W can be easily explained by the 
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extra tryptophan residue (wild-type NQO1 has six tryptophans), while the spectra of 
P187S has a max of 348 nm and a higher fluorescence intensity, suggesting some 
changes in the microenvironment of the tryptophan residues or lower quenching by 
the bound FAD molecules in this variant (Fig. 3d).  In the course of the purifications, 
we noticed the faint yellow colour of p.P187S in contrast to the wild-type and 
p.R139W. Indeed, the absorption (Fig. 3e) and circular dichroism spectra (Fig. 3f) in 
the Near-UV visible region reveal signals corresponding to FAD bound (with maxima 
at 370 and 450 nm) in the wild-type and p.R139W, while in the spectra for P187S 
these signals are approximately 10-fold weaker (Fig. 3e,f). 
 
To further characterize the binding of FAD to NQO1, we used isothermal titration 
calorimetry (ITC).  FAD binding to apo-wild-type and p.R139W showed complex 
behaviour, which was not consistent with the presence of one type of identical and 
independent sites. Analyses of the isotherms using a sequential binding model with 
two binding sites provide excellent descriptions for FAD binding to wild-type and 
p.R139W enzymes (Fig. 4a). These analyses showed that K1 far exceeds K2 (20-60 
fold), which is consistent with the presence of two independent and different types of 
sites or two identical and interacting types of sites displaying negative cooperativity 
(Table 2 and supplemental information).  In contrast, FAD binding to apo-p.P187S 
was well described by single type of independent and identical site (Fig. 4a), as shown 
by very good fits obtained to this model and the fact that K1 4·K2 in the sequential 
binding model (as expected for identical and independent sites, see Supplementary 
Material) (Table 2).  This variant displayed between 10-1000 fold lower binding 
affinity than wild-type and p.R139W (Table 2). This lower affinity in p.P187S 
explains why the FAD bound to this variant is much lower in the recombinant protein 
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as purified. Moreover, simulations of FAD binding as a function of its concentration 
showed that at physiological free FAD concentrations (58 nM [59]), the low affinity 
of p.P187S for FAD will result in a significant amount of apo-protein, which may be 
unstable intracellularly (Fig. 4b,c,d). 
 
The cancer-associated variants are unstable compared to the wild-type 
A common cause of loss of activity in disease-associated variants of proteins is 
reduced structural stability compared to the wild-type.  In native gel electrophoresis, 
p.R139W ran further than wild-type NQO1, most likely because of the change in 
isoelectric point resulting from altering a positively charged arginine residue to 
uncharged tryptophan [45].  p.P187S ran as a smear on the native gel in comparison to 
the more discrete bands observed for wild-type and p.R139W (Fig. 5a).  These results 
suggest that p.P187S is more prone to populate partially unfolded states consistent 
with our DLS analyses (Fig. 3a,b) and other previous results [19]. 
 
The melting temperatures of wild-type NQO1 and of each variant enzyme as 
determined by DSF were 50.6 ± 0.2 °C, 49.3 ± 0.2 °C and 43.3 ± 0.9 °C for 2 μM 
wild-type dimer, 2 μM p.R139W dimer (2μM dimer) and 10 μM p.P187S dimer  
respectively (means of three independent determinations ± standard deviation; Fig. 
5b).  The Tm values for wild-type NQO1 and p.R139W can be compared directly 
since their concentrations were equal; there was a slight, but significant, thermal 
destabilisation of the enzyme (p= 0.0007; t-test).  It was not possible to measure the 
melting temperature of p.P187S at a concentration of 2 μM protein, presumably due to 
the low level of bound FAD which gives rise to the fluorescence signal in the assay.  
p.P187S showed a concentration dependent melting temperature:  at 20 μM (dimer) it 
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had a Tm of 47.6±0.3 °C and at 10 μM the Tm was 43.3±0.9 °C.  This suggests that if 
it was possible to measure a melting temperature at 2 μM protein, it would be even 
lower than that recorded at 10 μM.  Thus, this protein is, by far, the most thermally 
unstable of the three studied here.  Susceptibility to limited proteolysis by trypsin 
increased in the order wild-type NQO1, p.R139W and p.P187S (Fig. 5c).  This 
mirrors the pattern observed in the enzymes’ melting temperatures. 
 
Thermal stability and FAD binding 
Thermal stability of NQO1 was studied in depth by differential scanning calorimetry 
(Fig. 6) and far-UV CD spectroscopy (Supplementary Fig. S4).. By both techniques, 
we observed a single thermal transition, with the polymorphisms reducing Tm values 
by ~2 K (p.R139W) and ~8 K (p.P187S) (Fig. 6a, Supplementary Fig. S4; Table 3). 
The decrease in thermal stability by p.P187S agreed well with previous thermal 
inactivation assays [19] and our DSF experiments (Fig. 5b). Thermal denaturation of 
NQO1 variants was irreversible (Fig. 6b), scan rate (Fig. 6c) and protein concentration 
dependent (Fig. 6d), indicating that their denaturation is kinetically-controlled and is 
likely to involve dissociation of native NQO1 dimers prior to the rate-limiting 
denaturation step [54-56].  Despite the heterogeneous mixture of species in the native 
state ensemble (with different degrees of saturation of the NQO1 dimers with FAD), 
we tentatively analyzed the DSC profiles using the simplest model that may account 
for their behaviour, a two-state irreversible model with non-first order kinetics 
(Scheme 1). This model reproduced the experimental DSC scans well (Fig. 6a), 
yielding consistent parameters for thermal denaturation (Ea and H values), and thus, 
it seems to be a reasonable description of the thermal denaturation of NQO1 (Table 3). 
Moreover, the model includes µ as a fitting parameter (where 1/µ is the reaction 
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order), which allows the estimation of the reaction order from the shape of thermal 
scan [56]:  when it is close to 1, the process is protein concentration independent (i.e. 
first-order), while a value close to 2 means that the process is protein concentration 
dependent and involves dissociation of NQO1 dimers prior to the rate-limiting 
denaturation step. Indeed, we obtain values of µ very close to 2 for wild-type and 
p.R139W, and somewhat lower for p.P187S, indicating dimer dissociation upon 
thermal denaturation for all three variants. 
 
We then obtained NQO1 variants in their apo-form and studied their stability by DSC. 
Removal of FAD bound has little effect on the Tm values (Table 2). The model used to 
describe thermal denaturation of NQO1 enzymes as purified also seems to be 
applicable to the apo-forms (Table 3). An interesting result found is that apo-NQO1 
wild-type and p.R139W enthalpy changes are much lower than those found for these 
variants as purified.  The Tm dependence of H values shows a linear dependence of 
3.90.5 kcal·mol-1·K-1, which is very close to the theoretical value for a protein of this 
size (3.8 kcal·mol
-1
·K
-1
) based on [60] (Fig. 6g). This result has two implications: first 
all apo-forms are expected to be natively folded (even though p.P187S seems to be 
more prone to form partially unfolded states, see [19] and Fig.3a, 5a,c); second the 
higher H values for wild-type and p.R139W as purified may arise from the 
dissociation of FAD, which shows binding enthalpies of 20-25 kcal·mol
-1
 (Table 2). 
 
We also investigated the possible effect of FAD on the thermal stability of NQO1 
variants (Fig. 6e,f; Supplementary Fig. S4b). Addition of FAD increased the Tm 
values for all three variants in a concentration dependent manner; this was somewhat 
stronger for p.P187S. This result is not unexpected, since the p.P187S has the lowest 
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occupancy of FAD binding sites in the absence of added FAD (Fig. 3e,f and [19]) and 
also lower affinity for this ligand [1] (Table 2).  Since thermal denaturation of NQO1 
is kinetically controlled, these results support the hypothesis that FAD kinetically 
stabilizes the NQO1 dimers thus increasing their denaturation half-lives, which is 
consistent with FAD binding at the dimer interface (Fig. 1; [5;61]). 
 
Quantitative estimation of changes in kinetic stability by polymorphisms and FAD 
binding 
To address, directly, the effect of polymorphisms on the kinetic stability of NQO1 as 
well as the stabilizing effect of FAD on them, we performed isothermal kinetic 
denaturation studies by Far-UV CD spectroscopy (Fig. 7).  To compare the three 
variants, we chose 37 °C and 42 °C because they allow determination of kinetic 
stability in a time window of several minutes to hours, and the results obtained can be 
considered as biologically relevant.  The apparent half-lives were estimated at 3.5 µM 
monomer by fitting to a single exponential function. In the absence of added FAD, the 
kinetic stability of NQO1 is reduced by ~7-fold and ~70-fold in p.R139W and 
p.P187S respectively at both 37 °C and 42 °C  (Fig. 7a,b). At 37 °C the half-life for 
denaturation is 9 min, 1.5 h and 9 h for p.P187S, p.R139W and wild-type NQO1 (Fig. 
7a), while their stability is about 6-fold lower at 42 °C (Fig. 7b). Addition of FAD 
increased the kinetic stability of the variants remarkably (Fig. 7c,d). Indeed, p.R139W 
and p.P187S reached the wild-type (as purified) level of kinetic stability at 
concentrations of 20 and ~250M of added FAD, respectively (Fig. 7d). Overall, 
our results show that the kinetic stability of p.P187S and p.R139W can be restored in 
vitro by addition of micromolar concentrations of FAD. 
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Discussion 
Our data demonstrate that both cancer-associated variants are destabilised compared 
to the wild-type protein in vitro; p.P187S is substantially more affected than p.R139W. 
Kinetic destabilization is overcome by addition of FAD in a concentration dependent 
manner, and this stabilization still increases at concentrations much higher than the Kd 
values for FAD, as seen by DSC thermal scan and kinetic denaturation studies by CD.  
This behaviour is a consequence of the kinetically controlled nature of NQO1 
denaturation. FAD mediated stabilization occurs even at concentrations of ligand at 
which the enzyme is close to be saturated possibly by reducing the fraction of 
unligated (no FAD bound) species kinetically sensitive to denaturation (see [56;62] for 
a detailed discussion of these kinetic models). Importantly, our in vitro stability 
analyses mirror the intracellular behaviour of p.P187S. In the absence of an 
exogenous supply of FAD, this variant is very unstable due to rapid proteasomal 
degradation, while addition of FAD (by riboflavin supplementation) increases the 
resistance towards proteasomal degradation in a concentration dependent manner 
[19;32]. Therefore, the in vitro and the intracellular instability of p.P187S are likely to 
have a common origin in the low thermodynamic stability of its apo-form and the low 
affinity of this variant for FAD. In turn, increasing FAD saturation may boost 
p.P187S stability by shifting the equilibrium towards the holo-form, and also enhance 
specific activity by overcoming the affinity defect of this variant for FAD. Our results 
also suggest a similar scenario for p.R139W, although in this case, we expect a less 
dramatic decrease in intracellular stability and a higher specific activity in the absence 
of FAD (or riboflavin) supplementation. 
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Previously, Moscovitz and coworkers were able to detect by mass spectrometry a 
population of partially unfolded states in apo-NQO1, while binding of FAD seems to 
shift the folding equilibrium towards the native dimer [19].  Our conformational and 
kinetic stability studies further support this study, and demonstrate that similar effects 
occur in p.P187S and p.R139W. The data of Moscovitz et al show that partially 
folded states are populated at low levels in the native state ensemble (see the low 
intensities of the partially unfolded vs. folded peaks in Figure 2 of [19]), and thus, 
they do not largely perturb the averaged molecular properties reported by us here. 
When corrected for the contribution of FAD binding, the denaturation enthalpies of all 
(apo-)NQO1 variants at their Tm are consistent with a folded native state based on 
well-known structure-energetics parameterizations (see Figure 5G), indicating that 
departures from the folded state (i.e. these partially unfolded states reported by 
Moscovitz, 2012 [19]) are marginal. Nevertheless, since these partially unfolded states 
may be more prone to aggregation and degradation than the native state, they may be 
critical to determine the kinetic stability in vitro (our work) and in cells [19]. By 
simply assuming that FAD binds and selectively stabilizes the native state, the 
partially unfolded states will be poorly populated in the holo-state, consistent with the 
results obtained by Moscovitz et al using mass spectrometry [19] and our thermal and 
kinetic stability studies.  Thus, FAD binding may enhance NQO1 activity by 
increasing the thermodynamic stability of the folded dimer under native conditions. 
Interestingly, Oliveberg and coworkers have shown that binding of copper and zinc 
ions to apo-SOD provides a larger thermodynamic stabilization that the sum of 
dimerization and monomer unfolding in the apo-state [63]. 
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Since p.R139W has comparable kinetic constants to wild-type NQO1, the explanation 
for its different behaviour in vivo may lie in its activity towards its natural electron 
acceptor substrates.  Previously, p.R139W has been shown to have a higher Km value 
for DCPIP but the same Km value for menadione; it also has a 60% lower activity in 
the reduction of mitomycin C (MMC) [45].  Therefore, p.R139W may have much 
higher Km values and/or lower kcat values for quinone substrates in vivo.  Its slightly 
decreased stability compared to wild-type NQO1 may also be a factor.  This variant 
may also be less effective at stabilising p53; irradiation-induced expression of p53 has 
been shown to be attenuated in cells expressing p.R139W [46].  Interestingly, in the 
structurally related enzyme NQO2, reduced oxidoreductase activity resulting from a 
common polymorphism (rs1143684; p.F47L) is associated with improved prognosis 
in some cancers [64-66].  This suggests that, despite structural and catalytic 
similarities between the two enzymes, their roles in the cell have important 
differences. 
 
As demonstrated here, the stability and oxidoreductase activity of p.P187S recovers in 
the presence of excess FAD. Recent studies on human cells which express this form 
of NQO1 have shown that supplementation of the cell growth media with the FAD 
precursor riboflavin causes stabilisation of p.P187S, leading to increased levels in the 
cells and increased NQO1 activity [19].  Taken together, this suggests that dietary 
supplementation with riboflavin-rich foods may be advisable for individuals with the 
p.P187S and p.R139W polymorphisms, especially those who are homozygous. This 
therapy resembles those used for different inborn errors of metabolism caused by 
protein instability, and based on vitamin and/or cofactor supplementation, some of 
which involve FAD-dependent enzymes [67-71]. Furthermore, our results predict that 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
23 
 
the levels of vitamin B2 required to rescue p.R139W will be lower than those required 
for p.P187S (see Figure 7).  Alternatively a “pharmacological chaperone” approach 
could be taken which would require the identification of a small molecule which 
would specifically and kinetically stabilise p.P187S and p.R139W, an approach 
previously shown to be successful in conformational metabolic diseases [68;72;73].  
Some of the methods for studying NQO1 stability described here, most notably DSF 
and DSC, may prove valuable in screening for and characterizing such compounds. 
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Figure Legends 
Figure 1:  Structure of human NQO1 showing the location of Arg139 and Pro187.  
One monomer of the NQO1 dimer is shown in green, with the FAD cofactor in yellow 
and the two residues in green; the other monomer is shown in grey.  In both 
orientations depicted, the active site lies above the FAD molecule.  The lower image 
shows the protein rotated 90° around the y-axis relative to the upper one.  The figure 
was constructed using data from PDB ID 2F1O [5] and PyMol (www.pymol.org). 
 
Figure 2:  Steady state enzyme kinetics for wild-type NQO1 and p.R139W.  The 
dependence of rate on NADH and NADPH concentration for wild-type NQO1 (top) 
and R139W (bottom) Rates measured at 37 °C with 70 μM DCPIP and 3 nM (dimer) 
wild-type NQO1 and  p.R139W for NADH and 1.5 nM (dimer) wild-type NQO1 and 
p.R139W for NADPH (0-350 μM) and 1.0 nM enzyme for NADPH (400 -550 μM). 
Each point represents the mean of three separate determinations and the error bars are 
the standard errors of these means. 
 
Figure 3:  Conformational properties and FAD binding to NQO1 enzymes. (A) 
Representative profiles of intensity vs. hydrodynamic radius for wild-type and 
p.P187S in the absence (solid line) and presence of 250 µM FAD; (B) Values of 
polydispersity and hydrodynamic radius as function of added FAD; data are means.d. 
from three independent experiments (C) Far-UV CD spectra at 5 µM protein 
monomer in the absence (solid lines) and presence of 50 µM FAD (dashed lines); D) 
Trp fluorescence emission spectra (exc=295 nm); E and F) Absorption (E) and CD (F) 
Near-UV/visible spectra without adding extra FAD (FAD must not be added because 
it may give a signal also as free FAD). In all panels, the color code is wild-type 
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(black), p.R139W (red) and p.P187S (blue). In panels C-F, data are from single 
measurements. 
 
Figure 4:  Titration of NQO1 variants with FAD and ligand binding analyses by a 
binding polynomial formalism. (A) Binding isotherms of NQO1 enzymes (5-6 M 
in dimer) titrated with FAD. Lines are best-fits to a sequential binding mechanism 
(wild-type and p.R139W) and a one independent and identical type of sites (p.P187S). 
Data are representative from two independent titrations. (B and C) Dependence of the 
mole fraction for different ligation species (solid line: 0, dimer with no FAD bound; 
dashed line: 1, dimer with 1 FAD bound; dotted line, 2, dimer with 2 FAD bound) 
for wild-type (black lines) and p.P187S (blue lines) on free (B) and total (C) FAD 
concentration for 1 M NQO1 dimer. (D) Dependence of the binding capacity 
(number of FAD molecules bound per NQO1 dimer) on the total FAD concentration 
for 0.1 (solid lines), 1 (dashed lines) and 10 (dotted lines) M NQO1 dimer. Black 
lines are for wild-type and blue lines for p.P187S. 
 
Figure 5:  Stability of NQO1 variants.  (A) Tris glycine native PAGE: 3 μM dimer 
of each protein was electrophoresed on a 10 % gel at pH 8.8.  (B)  Differential 
Scanning Fluorimetry: Thermal melt comparison for wild-type NQO1, p.R139W and 
p.P187S triplicate samples of wild-type NQO1 (2 μM dimer), p.R139W (2 μM dimer) 
and p.P187S (10 μM dimer) in HEPES-OH, pH 7.33 were subjected to an increase in 
temperature from 25 °C to 95 °C in 1 K increments with excitation at 460 nm and 
emission measured at 510 nm throughout thereby exploiting the fluorescence of the 
cofactor, FAD.  Upper panel:  the fluorescence emitted throughout the experiment;  
Lower panel: the first derivative of this fluorescence emission graph plotted against 
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temperature.  (C) Limited proteolysis by trypsin.  Protein samples (3.5 μM dimer) 
with increasing concentrations of trypsin: 0, 9, 36, 63, 90, 360, 630, 900 nM.  Trypsin 
was dissolved in buffer R supplemented with 2 mM CaCl2. Results are representative 
of three independent experiments. 
 
Figure 6:  DSC profiles of NQO1 variants. (A) DSC scan at 2 K/min and 10 µM 
monomer NQO1. Lines are best-fits to a two-state irreversible model with non-first 
order kinetics. (B) Irreversibility of thermal denaturation. The solid lines are scans up 
to 80 °C, dashed lines first-scans to a temperature close to the completion of the 
transition, and dotted lines are second-scans upon cooling down to 5 °C. Performed at 
3 K/min and 5 µM monomer NQO1. (C) Scan rate dependence of the Tm values. 
Performed at 10 µM monomer NQO1. (D) Protein concentration dependence of Tm 
values. Performed at 3
 
K/min. (E) DSC profiles of p.P187S in the presence of 
different FAD concentrations. Lines are best-fits to a two-state irreversible model 
with non-first order kinetics. Performed at 3 K/min and 10 µM monomer NQO1.  (F) 
Dependence of the Tm values on FAD concentration. Performed at 3K/min and 10 µM 
monomer NQO1. (G) Denaturation enthalpies of NQO1 enzymes and structure-
energetic correlations. Values from single scans are shown as small symbols, while 
large symbols are the means.d. Closed circles are for NQO1 enzymes as purified, 
and open triangles for apo NQO1 enzymes (panels c, d, g). The blue line is the linear 
fit of the data for apo-proteins linear fit providing a slope (Cp) of 3.90.5 kcal·mol
-1
 
which agrees excellently with the theoretical value of 3.8 kcal·mol
-1
 from the 
parametrization of [60] for a folded protein of this size based on the number of 
residues. Note that the enthalpy values for NQO1 WT and p.R139W are ~40 kcal·mol
-
1
 higher than those found for their apo-NQO1 forms, probably due to the contribution 
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of FAD release upon denaturation. In panels C, D, F and G, the values displayed for 
single experiments are best-fit values to the two-state kinetic model (equations 1-3 in 
supplementary data) and fitting errors are 0.1oC (for Tm values) and <3 kcal·mol
-1
 
(for H values). 
Figure 7:  Kinetic denaturation studies by CD spectroscopy. (A and B) kinetic 
traces for denaturation of NQO1 variants without added FAD at 37 °C (A) and 42 °C 
(B). (C) kinetic traces for p.P187S in the presence of different FAD concentrations at 
42 °C. In panels A-C, lines are best fits to a single exponential function. (D) FAD 
concentration dependence of the apparent denaturation half-life of p.R139W and 
p.P187S at 42 °C. For sake of comparison, the denaturation half-life for wild-type at 
this temperature without added FAD is shown as a horizontal dashed line. In panel D, 
data are best-fit values obtained from single experimental using a single exponential 
function, and fitting errors are lower than 10% of the best-value half life. 
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Tables 
Table 1  Steady-state kinetic parameters for wild-type NQO1 and p.R139W.  
 Wild-type NQO1 p.R139W NQO1 
 NADH NADPH NADH NADPH 
Km,app /µM
 
240 ±34 154 ±38 256 ±48 138 ±24 
kcat,app /s
-1 
186 ±12* 732 ±68 356 ±31* 598 ±37 
kcat/Km/μM
-1
s
-1 
0.8 ±0.2* 4.8 ±1.6 1.4 ±0.4* 4.3 ±1.0 
h 1.05 ±0.05 1.10 ±0.10 1.11 ±0.04 1.14 ±0.12 
 
Rates measured at 37 °C with varying concentrations of electron donor (NADH or 
NADPH) and a constant concentration of electron acceptor, (DCPIP, 70 μM) 
background rates for the non-enzymatic reduction of DCPIP at each concentration of 
electron donor subtracted to give the enzyme catalysed rate.  Values were derived 
from non-linear curve fitting of triplicate data.  Values marked * are significantly 
different (p<0.05; F-test) between the wild-type and p.R139W. 
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Table 2. Thermodynamic parameters for the binding of FAD to NQO1 variants.  Data 
are the mean from two independent titrations. 
 
Sequential binding (two sites) 
 K1 
(M
-1
) 
H1 
(kcal·mol
-1
) 
S1 
(cal·mol
-1
·K
-
1
) 
K2 
(M
-1
) 
H1 
(kcal·mol
-
1
) 
S1 
(cal·mol
-
1
·K
-1
) 
Wild-
type 
1.1·109 -19.2 -23.1 1.7·10
7
 -25.5 -52.4 
p.R139W 3·108 -16.4 -16.5 1.4·10
7
 -23.7 -46.7 
p.P187S 5.5·10
6
 -18.0 -29.4 1.1·10
6
 -16.0 -21.2 
Identical, independent type of sites 
 N K (M
-1
) H 
(kcal·mol
-1
) 
S 
(cal·mol
-1
·K
-1
) 
p.P187S 2.0 2.1·10
6
 -17.3 -29.0 
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Table 3. Energetic parameters for thermal denaturation of NQO1 enzymes 
 
NQO1 
variant 
Tm (
o
C)
a
 ΔH (kcal·mol-1)b,c Ea (kcal·mol
-1
)
b 
µ
b,c
 
Wild-type 
(apo) 
52.51±0.06 
(51.870.03) 
100.1±6.0 
(64.55.6) 
44.3±5.8 
(67.29.6) 
2.6±0.5 
(1.90.4) 
p.R139W 
(apo) 
50.39±0.04 
(50.070.02) 
99.4±5.6 
(52.76.3) 
48.9±5.5 
(80.74.2) 
2.0±0.3 
(1.50.1) 
p.P178S 
(apo) 
43.83±0.02 
(44.550.02) 
32.7±2.2 
(30.96.2) 
82.8±4.5 
(94.66.2) 
1.4±0.1 
(1.20.1) 
 
a
 At 3 K/min and 10 µM in monomer. Data are from single experiments and errors are 
from fittings to a two-state kinetic model (equations 1-3 in supplementary text). 
b 
mean±s.d. from six five different experiments at different scan rates (1-3 K/min) and 
protein concentrations (5-30 µM in monomer). 
c
 expressed per NQO1 monomer. 
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FAD binding overcomes defects in activity and stability displayed by 
cancer-associated mutations of human NQO1 
 
Highlights 
 
 Cancer-associated variants of NQO1 are less active and less kinetically stable 
 p.P187S decreases FAD binding and thermodynamic stability 
 FAD corrects stability and activity defects in polymorphic NQO1 forms  
 Patients may respond positively to vitamin B2 supplementation 
